NCT04731116 is a Phase 1, PHASE2 clinical trial of Cannabidiol in COVID-19, sponsored by Rabin Medical Center.

Who is sponsoring NCT04731116?

NCT04731116 is sponsored by Rabin Medical Center.

What drugs are being tested in NCT04731116?

Interventions in NCT04731116: Cannabidiol.

Is NCT04731116 still recruiting?

NCT04731116 is currently status unknown. Last updated 29 January 2021.

Last reviewed 2021-01-29 · How we verify

NCT04731116

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cannabidiol Treatment for Severe and Critical Coronavirus (COVID-19) Pulmonary Infection

Status unknown Phase 1, PHASE2 Last updated 29 January 2021

What this trial tests

Phase 1, PHASE2 trial testing Cannabidiol in COVID-19 in 40 participants. Status unknown.

Timeline

10 January 2021

Primary endpoint
31 December 2021

30 April 2022

Quick facts

Lead sponsor	Rabin Medical Center
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	10 January 2021
Primary completion	31 December 2021
Estimated completion	30 April 2022
Sites	1 location across Israel

Drugs / interventions tested

Cannabidiol (CANNABIDIOL) — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Rabin Medical Center

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Current management of COVID-19 (coronavirus) is mainly supportive, and respiratory failure from acute respiratory distress syndrome (ARDS) is the leading cause of mortality. Cytokines and chemokines are thought to play an important role in immunity and immunopathology during virus infections. Patients with severe COVID-19 have higher serum levels of pro-inflammatory cytokines (TNF-α, IL-1 and IL-6) and chemokines (IL-8) compared to individuals with mild disease or healthy controls, similar to patients with severe acute respiratory syndrome (SARS). Cannabidiol (CBD), a nonpsychotropic ingredient of Cannabis sativa, possesses potent anti-inflammatory and immunosuppressive properties. These effects are mediated by T cell attrition and by inhibition of pro-inflammatory cytokine release (tumor necrosis factor-a, Interferon gamma, IL-1b, IL-6, and IL-17) and stimulation of anti-inflammatory cytokine production (IL-4, IL-5, IL-10, and IL-13). In a number of phase 2 trials involving more than 100 patients, our group was able to show the safety and efficacy of CBD in the prevention and treatment of graft-versus-host disease. Based on these data, we will test the cytokine profile, safety and efficacy of CBD treatment in patients with severe and critical COVID-19 infection.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Traditional Herbal Medicines, Bioactive Metabolites, and Plant Products Against COVID-19: Update on Clinical Trials and Mechanism of Actions.
Alam S, Sarker MMR, Afrin S, Richi FT, et al · · 2021 · cited 61× · PMID 34122096 · DOI 10.3389/fphar.2021.671498
Cannabidiol inhibits SARS-Cov-2 spike (S) protein-induced cytotoxicity and inflammation through a PPARγ-dependent TLR4/NLRP3/Caspase-1 signaling suppression in Caco-2 cell line.
Corpetti C, Del Re A, Seguella L, Palenca I, et al · · 2021 · cited 50× · PMID 34643000 · DOI 10.1002/ptr.7302
<i>In silico</i> investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective.
Rahman MM, Islam MR, Akash S, Mim SA, et al · · 2022 · cited 18× · PMID 36072227 · DOI 10.3389/fcimb.2022.929430
Stroke in SARS-CoV-2 Infection: A Pictorial Overview of the Pathoetiology.
Aghayari Sheikh Neshin S, Shahjouei S, Koza E, Friedenberg I, et al · · 2021 · cited 18× · PMID 33855053 · DOI 10.3389/fcvm.2021.649922
In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir.
Zhang Q, Melchert PW, Markowitz JS. · · 2022 · cited 10× · PMID 35964681 · DOI 10.1016/j.cbi.2022.110097
Multifaceted roles of plant derived small molecule inhibitors on replication cycle of SARS-CoV-2.
Uma Reddy B, Routhu NK, Kumar A. · · 2022 · cited 7× · PMID 35381324 · DOI 10.1016/j.micpath.2022.105512
Rational drug repositioning for coronavirus-associated diseases using directional mapping and side-effect inference.
Wang J, Liu J, Luo M, Cui H, et al · · 2022 · cited 5× · PMID 36267550 · DOI 10.1016/j.isci.2022.105348
The immunology and immunotherapy for COVID-19.
Liu Y, Zhou X, Liu X, Jiang X. · · 2021 · cited 3× · PMID 34915958 · DOI 10.1017/erm.2021.30

Verify or expand the search:

Other trials of Cannabidiol

Trials testing the same drug.

NCT07527338 — Mechanisms of Cannabidiol and Sleep in the Context of Alcohol Use · Phase 2, PHASE3 · not yet recruiting
NCT07278505 — Study of Cannabidiol and Neuroimaging on Stress · Phase 1, PHASE2 · recruiting
NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors · Phase 2 · recruiting
NCT06381180 — Warrior CARE: Cannabis Behavioral Health · Phase 1, PHASE2 · not yet recruiting
NCT06854783 — Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers · Phase 1 · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Rabin Medical Center trials

Trials by the same sponsor.

NCT06837909 — Transversus Abdominis Plane Block Versus Wound Infiltration for Pulmonary Function Preservation Following Laparoscopic L · NA · recruiting
NCT06951399 — Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07208240 — Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST T · Phase 1, PHASE2 · recruiting
NCT06931119 — Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients · Phase 1 · not yet recruiting
NCT06966427 — Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Inje · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04731116 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rabin Medical Center
Last refreshed: 29 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04731116.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing